View in EDS HTML Full Text PDF Full Text

Targeted β−-Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.

Saved in:
Bibliographic Details
Title: Targeted β−-Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
Authors: Fricke, Julia G.1 (AUTHOR), Westerbergh, Frida2 (AUTHOR), McDougall, Lisa1 (AUTHOR), Favaretto, Chiara1,3 (AUTHOR), Christ, Emanuel4,5 (AUTHOR), Nicolas, Guillaume P.1,4 (AUTHOR), Geistlich, Susanne3 (AUTHOR), Schmid, David E.3 (AUTHOR), Borgna, Francesca3 (AUTHOR), Fani, Melpomeni6 (AUTHOR), Bernhardt, Peter2,7 (AUTHOR), van der Meulen, Nicholas P.3,8 (AUTHOR), Müller, Cristina3,9 (AUTHOR), Schibli, Roger3,9 (AUTHOR), Wild, Damian1,4 (AUTHOR) damian.wild@usb.ch
Source: Journal of Nuclear Medicine. Mar2026, Vol. 67 Issue 3, p416-422. 7p.
Database: Engineering Source
Full text is not displayed to guests.
Description
ISSN:01615505
DOI:10.2967/jnumed.125.270654